Dose-escalating open-label trial to assess the tolerability of IPP 204106 in patients with various cancers, including breast cancer, lung cancer and bladder cancer with at least one treatment failure.
Phase of Trial: Phase I/II
Latest Information Update: 08 Oct 2012
At a glance
- Drugs IPP 204106 (Primary)
- Indications Bladder cancer; Breast cancer; Cancer; Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2012 Status changed from recruiting to completed, according to an ImmuPharma media release.
- 06 Dec 2010 New trial record
- 19 Nov 2010 Brief preliminary results have been reported in an ImmuPharma media release.